ENTITY
Transcenta

Transcenta (6628 HK)

17
Analysis
Health Care • China
Transcenta is a clinical-stage biopharmaceutical company with integrated capabilities in the discovery, research, development, manufacturing, and business development of biopharmaceuticals. The company develops therapeutic antibody molecules for oncology and selected non-oncology indications, including bone and kidney disorders, and also provides contract development and manufacturing organization (CDMO) services. Transcenta is headquartered in Suzhou, China, and was founded in 2010.
more
bearish•Transcenta
•28 Sep 2021 10:39

Transcenta (创胜) IPO Trading: Share Concentration

We look at the updates of Transcenta IPO since our last note. We think the debut performance is likely poor given the lack of interest and the fair...

Logo
409 Views
Share
bullish•Biel Crystal
•19 Sep 2021 10:10

ECM Weekly (19th September 2021) - PHC, StarHealth, TDCX, Biel Crystal, DRCBank, Transcenta, Broncus

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Logo
638 Views
Share
bearish•Transcenta
•15 Sep 2021 21:17

Transcenta (创胜) IPO: Fairly Valued Despite Downsizing

We provide an update of the deal terms and the valuation for the Transcenta's book building. We think the deal is fairly valued despite its...

Logo
509 Views
Share
bearish•Transcenta
•22 Jul 2021 09:09

Pre-IPO Transcenta Holding - Insights on Pipeline and the Concerns

The article mainly analyzed Transcenta Holding in terms of its important product candidates MSB2311, TST001, TST005 and MSB0254,including the...

Logo
411 Views
Share
bullish•Transcenta
•19 Jul 2021 09:36

Transcenta (创胜) Pre-IPO: Thoughts on Valuation

We provide a pre-money valuation for Transcenta's key products, including MSB2311 (next generation PD-L1) and TST001 (Claudin 18.2) in this note.

Logo
533 Views
Share
x